KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Interest & Investment Income (2016 - 2025)

Vertex Pharmaceuticals has reported Interest & Investment Income over the past 17 years, most recently at $121.9 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $121.9 million for Q4 2025, down 4.91% from a year ago — trailing twelve months through Dec 2025 was $490.9 million (down 17.92% YoY), and the annual figure for FY2025 was $490.9 million, down 17.92%.
  • Interest & Investment Income for Q4 2025 was $121.9 million at Vertex Pharmaceuticals, down from $125.7 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for VRTX hit a ceiling of $181.2 million in Q1 2024 and a floor of $1.1 million in Q2 2021.
  • Median Interest & Investment Income over the past 5 years was $122.2 million (2025), compared with a mean of $92.7 million.
  • Biggest five-year swings in Interest & Investment Income: tumbled 88.07% in 2021 and later skyrocketed 7562.5% in 2023.
  • Vertex Pharmaceuticals' Interest & Investment Income stood at $1.2 million in 2021, then surged by 7066.67% to $86.0 million in 2022, then soared by 108.72% to $179.5 million in 2023, then fell by 28.58% to $128.2 million in 2024, then dropped by 4.91% to $121.9 million in 2025.
  • The last three reported values for Interest & Investment Income were $121.9 million (Q4 2025), $125.7 million (Q3 2025), and $122.4 million (Q2 2025) per Business Quant data.